David (Dave) Moore has served as the Chairman of the Board of Directors of Novasenta since mid-2023. Dave brings over 20 years of biopharma operational and executive management experience to Novasenta. He is currently the Executive Vice President of Corporate Development at Novo Nordisk U.S., where he is responsible for corporate strategy, business development, integration and strategic alliances. Previously at Novo Nordisk U.S., Dave also worked as Senior Vice President, Commercial, where he led the successful transformation of the company’s commercial operating model into a purely integrated sales and marketing organization. He led the company through multiple new product launches, including one of the most successful launches in Type 2 diabetes to date.
Dave has also worked in other leadership roles as the CEO at Roivant Sciences, a biopharmaceutical drug development company, focusing on infectious disease and as Managing Partner with Gurnet Point Capital, a private equity firm that invests in de-risked life sciences companies.
He holds a degree in biology from Towson University, an MBA from Lehigh University and completed the graduate program in population health and healthy policy at Thomas Jefferson University.